Abstract. During the purification of laminin–proteoglycan complexes from rat RN22 Schwannoma cell-conditioned medium, a laminin-rich fraction was obtained which lacked neurite-promoting activity. Since laminin from several sources is known to have potent neurite-promoting activity, this result suggested that either this laminin was inactive or its activity was somehow masked by associated molecule(s). The latter possibility was supported by the demonstration that the inactive laminin-containing fraction inhibited active laminin-containing fractions. This inhibitory activity was partially purified by using ion exchange chromatography and isopycnic centrifugation. The purified material contained proteoglycan based on its high affinity for cationic resin, high buoyant density, large heterodisperse appearance on electrophoretic gels, ability to label with inorganic sulfate, sensitivity to trypsin and glycosaminoglycan lyases, and heat stability.

A quantitative in vitro bioassay was used to monitor the inhibitor after treatments aimed at defining its activity. The isolated Schwannoma-derived inhibitor (a) inhibits the neurite-promoting activity of purified rat, mouse, and human laminin; (b) is active whether presented to laminin in solution or after either the inhibitor or laminin is first bound to the culture substratum; (c) does not act by displacing laminin from the substratum; (d) can be prevented from binding to neurite-promoting laminin substrates by polyclonal and monoclonal anti-laminin or polyclonal anti-entactin antibodies; and (e) is abolished by proteases or glycosaminoglycan lyases but not by heat. The above results suggest that the neurite-promoting activity of laminin is subject to regulation through association with a proteoglycan and entactin.
Inhibition and Induction of Neurite Outgrowth

Neurite promotion and inhibition were assayed as substratum-bound activities on polyornithine-coated tissue culture wells (Manthorpe et al., 1983).

Materials and Methods

Isolation of $^{35}$S-labeled Schwannoma Neurite-promoting and Inhibitory Activities

Growth conditions for the rat RN22 Schwannoma cells and the methods for labeling with $^{35}$SO$_4$ have been described (Davis et al., 1987). 8 liters of RN22 conditioned medium containing 80 ml $^{35}$S-labeled RN22 medium was first applied to a 100 ml bed volume DEAE (DE52: Whatman, Inc., Clifton, NJ) ion-exchange column (2.5-cm-diam) and eluted with a 600-ml linear salt gradient from 0.15-0.6 M NaCl in 10 mM phosphate buffer, pH 8.0. Laminin immunoreactivity began to elute at 0.3 M NaCl in the gradient and overlapped with the elution of radioultrated material (see Results). Fractions eluted between 300 and 420 ml of the gradient were pooled and diluted to 0.15 M NaCl and phosphate buffer (10 mM, pH 8.0). This diluted pool was applied to a 10-ml bed volume DEAE column and bound material was eluted using a 60-ml NaCl gradient (0.15-0.6 M). The laminin immunoreactivity which eluted at 0.2-0.3 M NaCl was collected and pooled (POOL I). Also, the inhibitory activity (see below) began to elute at 0.3 M NaCl and was also collected and pooled (POOL II). POOL II was concentrated by ultrafiltration using an XM100 membrane (Amicon Corp., Danvers, MA) and dialyzed against 0.4 M guanidine-HCl in 50 mM Tris-HCl, pH 7.5. Solid CsCl was added to give density of 1.35 g/ml and samples were subjected to isopycnic centrifugation at 180,000 g for 48 h. High density fractions (>1.5 g/ml) were pooled (POOL A) and dialyzed against PBS, pH 7.2. Laminin antigen was measured by an ELISA (Engvall, 1980) performed in polystyrene, 96-well plates using monoclonal and monoclonal antibodies as previously described (Davis et al., 1985a). Fractions were assayed for neurite-promoting activity using 8-d ciliary ganglion neurons (Manthorpe et al., 1981, 1983). Radioactivity was monitored by liquid scintillation. Protein was measured by the method of Lowry et al. (1951) using BSA as a standard. Glycosaminoglycan content was measured by Alcian blue binding assay (Engvall, 1980) performed in polystyrene, 96-well plates using polyclonal and monoclonal antibodies as previously described (Davis et al., 1985a). To address whether proteoglycan is involved in the inhibitory activity, we cultured the RN22 cells in the presence of an inhibitor of proteoglycan assembly, 4-methylumbelliferyl-β-D-xiosyl dehydrochondroitin sulfate (Sigma Chemical Co., St. Louis, MO) as standards according to Bartold and Page (1985).

Gel Electrophoresis, Immunoblotting, and Autoradiography

SDS-PAGE (4-12% T) was run under reducing conditions using the buffer conditions of Laemmli (1970). Unstained gels were electrophoretized to nitrocellulose sheets by the method of Towbin et al. (1979) and the blots were immunostained for laminin as described by Davis et al. (1985a) or stained by colloidal gold using colloidal gold (Sigma Chemical Co., St. Louis, MO) as standards according to Bartold and Page (1985). To address whether proteoglycan is involved in the inhibitory activity, we cultured the RN22 cells in the presence of an inhibitor of proteoglycan assembly, 4-methylumbelliferyl-β-D-xiosyl dehydrochondroitin sulfate (Sigma Chemical Co., St. Louis, MO) as standards according to Bartold and Page (1985).

Enzyme Digestion

Some test samples were treated with proteolytic lyases or proteolytic enzymes for assay or activity analysis by SDS-PAGE. For analysis of proteoglycans, samples were incubated for 3 h at 37°C with heparitinase A (Becton Dickinson, Clifton, NJ) as described above. We define the half maximal inhibition as 1 neurite inhibitory unit (NIU) and the unit in NIU/ml as that dilution of test sample (total volume = 50 µl) added to the well during substratum treatment eliciting 1 NIU.

Results

Fractionation of RN22-derived Neurite-promoting and Inhibitory Activities

Fractionation of RN22-conditioned medium on DEAE cellulose is shown in Fig. 1. Over 95% of the recovered protein eluted as one early peak before 0.25 M NaCl while two peaks of laminin antigen eluted with ~0.3 and 0.4 M salt. The first and second laminin peaks represented about one-third and two-thirds, respectively, of the total recovered laminin antigen measured by an ELISA using rabbit polyclonal anti-rat laminin antisera. Over 95% of the recovered radioactivity eluted in one peak immediately after, and overlapping with, a second laminin peak. Essentially these same elution profiles were obtained using the previous smaller scale fractionation (Davis et al., 1987).

The previous study (Davis et al., 1987) indicated that the overlapping laminin and $^{35}$SO$_4$ peaks from the DEAE column contained laminin–proteoglycan complexes possessing neurite-promoting activity. In an attempt to resolve free laminin, free proteoglycan, and laminin–proteoglycan complexes, the overlapping laminin and $^{35}$SO$_4$ fractions were pooled as indicated in Fig. 1, diluted and fractionated on a second, smaller DEAE column (Fig. 2). The radioactivity eluted in a slightly broader and earlier peak with 0.3–0.5 M NaCl (Fig. 2A) as compared with the first column (cf. Fig. 1). The laminin antigen (measured by ELISA using polyclonal anti-rat laminin) eluted as two broad and slightly overlapping peaks with ~0.2–0.3 M and 0.3–0.4 M NaCl and these peaks contained about one- and two-thirds, respectively, of the recovered antigen. Thus, the single laminin–$^{35}$SO$_4$ peak from the first column resolved in the second column into two laminin peaks,

1. Abbreviations used in this paper: NIU, neurite inhibitory unit; NPU, neurite-promoting unit.

The Journal of Cell Biology, Volume 109, 1989 2354
one of which was associated with nearly all the recovered 35S-radioactivity. The elution of two laminin peaks from the second DEAE column occurred with a little less salt concentration as that of the laminin from the first column. This result suggests that the laminin-35S04 peak from the first column contained laminin-proteoglycan complexes from which the laminin component can be released with additional fractionation.

When these same fractions from the second DEAE column were examined for laminin antigen using the mouse monoclonal antibody, termed 2E8, the majority of immunoactivity was found in one peak which eluted before the peak of radioactivity. In fractions containing most of the 35S-radioactive material, laminin antigen could only be detected by the polyclonal antibodies. Since the 2E8 antibody is known to bind to an epitope located in the cross region of laminin on the 200-kD B subunit (Engvall et al., 1986), these results suggest that in the radioactive peak fractions the 2E8 epitope of the laminin B chain is either missing or masked. However, 2E8 immunoactivity was demonstrated on western blots of the same column fractions (Fig. 2 B) showing that the 2E8 epitope was present in fractions containing the peak of 35S radioactivity but apparently was prevented from interacting with the 2E8 antibody in the ELISA.

 Autoradiography on the immunoblots revealed two bands of 35S-radioactivity, neither of which comigrated with laminin polypeptides (Fig. 2 C). One radioactive band was broad, diffuse, and in a region corresponding to a relative molecular mass of 300-900 kD and is likely to contain radiosulfated proteoglycan. The other band was focussed at 150 kD and comigrated with the sulfated, laminin-binding protein, entactin (Paulsson et al., 1987). Immunoblots of these same DEAE fractions using anti-entactin antibodies showed staining of this 150-kD radiosulfated band, thus supporting its identification as entactin (data not shown).

Each fraction of the second DEAE column was examined and scored as containing (+) or not containing (-) neurite-promoting activity using the CG13 test neurons. The results are depicted in Fig. 2 D. At the concentration tested (20 μl of sample plus 30 μl buffer per well) all fractions expressed neurite-promoting activity except in those associated with the peak of 35S-radioactivity. Thus, the lack of neurite-promoting activity correlated with the presence of proteoglycan and entactin and the absence of monoclonal antibody 2E8 binding. However, significant amounts of laminin antigen are detected by immunoblotting in these same peak radioactive fractions (cf. Fig. 2), suggesting that the neurite-promoting activity, like the 2E8 epitope, was masked by material within the peak 35S-radiolabeled fractions, e.g., by proteoglycan and/or entactin.

**Inhibition of Laminin Neurite-promoting Activity**

Next, we explored more directly whether the peak of 35S-radioactivity in POOL II contained a material that could inhibit the neurite-promoting activity of the laminin in POOL I. Pools I and II were tested for neurite-promoting activity separately and after combination. Results are shown in Fig. 3. When POOL II was combined with the neurite-promoting POOL I, this activity was no longer detected (Fig. 3 C). Thus, POOL II contains an activity capable of eliminating the neurite-promoting activity in POOL I. Purified mouse, rat, and human laminin, all previously shown to possess potent neurite-promoting activity (Engvall et al., 1986; Mantorpe et al., 1983; Wewer et al., 1983), were similarly inhibited by POOL II (data not shown).

To monitor and characterize the inhibitor in more detail, we used a quantitative bioassay as described in Materials and Methods. When serial dilutions of POOL II were incubated in wells treated with 500 ng/ml × 50 μl/well (25 ng/well) of laminin, a concentration-dependent inhibition of the laminin activity was observed. The results are shown in Fig. 3 D.

**Characterization of the Schwannoma-derived Neurite Inhibitor**

The inhibitory material eluted relatively late from the DEAE column (Fig. 2) and was associated with 35S04-labeled material, suggesting that it may contain proteoglycan. To isolate this component, POOL II was submitted to fractionation by isopycnic centrifugation on a CsCl gradient. The CsCl density gradient fractions were examined for radioactivity, laminin immunoreactivity, neurite-promoting, and inhibitory activities. The results are shown in Fig. 4. Most of the radiosulfated material had a high buoyant density (>1.5 g/ml) although a small proportion of radioactivity appeared at a lower density (1.35 g/ml). The high density fractions lacked laminin immunoreactivity (using polyclonal antibodies in ELISA) and contained inhibitory activity (Pool A). Laminin antigen was present as a distinct peak (1.35 g/ml) which contained neurite-promoting activity (Pool B). Apparently the high ionic strength of this gradient (0.4 M guanidine-HC1 and 8 M CsCl) effectively separated neurite-promoting activity from inhibitory activity. Thus, when POOL II samples containing laminin but no neurite-promoting activity were subjected to isopycnic centrifugation, neurite-promoting activity was recovered.

The neurite-promoting and inhibitory activities of fractions obtained during various fractionation steps are shown in Table I. The inhibitory activity recovered in the high den-
Figure 2. Further fractionation of the laminin and \(^{35}\)S-labeled DEAE fraction by a second DEAE ion-exchange step. Fractions 30–42 from the first DEAE step (see Fig. 1) were diluted to 0.15 M NaCl and applied to a 6-ml DEAE column from which bound material was eluted in 1-ml fractions by a 60-ml 0.15–0.6 M linear NaCl gradient (represented by a line connecting the onset and completion of the elution). (A) Fractions were assayed for radioactivity (○) and laminin immunoactivity in an ELISA using a polyclonal antiserum (●) and monoclonal antibody No. 2E8 (▲). Bars indicate POOL I (fractions 4–12) and POOL II (fractions 20–32). (B) Western blots from reducing SDS gel profiles of every fifth fraction (20 μl) were immunostained for laminin with monoclonal No. 2E8. Arrow indicates a relative molecular
Figure 3. Bioassay of substratum-bound neurite-promoting and neurite-inhibiting activities derived from Schwannoma-conditioned medium. Purified embryonic day 8 ciliary ganglion neurons were cultured according to Material and Methods on polyornithine-coated tissue culture wells pretreated with samples from DEAE ion-exchange (A) POOL I, (B) POOL II, and (C) POOL I and POOL II combined, each diluted 1:10 in a volume of 50 μl. Phase-contrast photomicrographs were taken after 4 h in culture. (D) A maximal neurite-promoting response by CG neurons was achieved by incubating the polyornithine-wells with 50 μl of 500 ng/ml (25 ng/well) of purified rat laminin (○). A titration curve for the inhibitory activity of POOL II sample (●) indicates a titer of 65 NIU/ml. CG neurons were seeded and maintained for 4 h before assessing the percentage of cells bearing neurites greater than four cell diameters. Assays counting 50–100 neurons per well were performed in duplicate and the data points represent the mean from four experiments. Standard deviations were <5%. Bars, 50 μm.

Given that laminin is heat sensitive (Ott et al., 1982) while proteoglycans are often heat stable, we attempted to destroy selectively the laminin activity by heat treatment and thereby possibly release inhibitor from laminin–inhibitor complexes. The results are shown in Table I. Heat treatment (90°C, 15 min) of conditioned medium from RN22 cells and of the laminin-radiosulfated pool from the first DEAE step resulted in a mass of 200 kD. (C) The western blot shown in B was exposed to x-ray film for 3 d and developed. The arrows indicate molecular mass markers: rat yolk sac laminin (400 and 200 kD) and entactin (150 kD). (D) An aliquot (20 μl) of each of the fractions from the second DEAE column elution was examined for neurite-promoting activity using ciliary ganglion test neurons and scored as containing (+) or not containing (–) such activity.
Figure 4. Isopycnic centrifugation of the neurite inhibitor. For buoyant density analysis, POOL II (from the DEAE fractionation step shown in Fig. 3) was made 0.4 M in guanidine-HCl, adjusted to 1.35 g/ml with crystalline CsCl, and then centrifuged. Gradient fractions were assayed for 35S-radioactivity (●), laminin immunoreactivity in an ELISA using polyclonal antibodies (○), and for the presence of neurite-promoting activity (POOL B), and inhibitory activity (POOL A) (top horizontal bars).

The entire loss of neurite-promoting activity and the appearance of inhibitory activity. Heat treatment of POOL I samples from the second DEAE step eliminated its neurite-promoting activity but generated no inhibitory activity in accordance with the view that this material contains laminin but no inhibitor. When Pool II samples were heated, the titer of the inhibitory activity increased approximately fourfold. Thus, exposure of POOL II to heat (to inactivate laminin neurite-promoting activity) increased its inhibitory activity to about the same extent as does the isopycnic centrifugation (which separated inhibitor from laminin neurite-promoting activity). The specific activity of the inhibitor from the CsCl gradient pool (Fig. 4) was ~17,000 inhibitory units/mg protein, representing a 90,000-fold increase over the serum-containing conditioned medium starting material (after heating).

The inhibitory fractions from the CsCl gradient were pooled (POOL A) and analyzed by SDS-PAGE and electroblotting. The results are shown in Fig. 5. Sensitive protein staining revealed a major band with an apparent molecular mass of 150 kD and a few minor bands (lane 1). The 150-kD band reacted with anti-entactin antibodies but no laminin immunoreactivity was detected (results not shown). Autoradiography of the radiosulfate labeled material showed a broad band that was most dense in a region corresponding to a relative molecular mass of 300–400 kD, and a narrow 150-kD band (lane 2). The electrophoretic mobility of the high molecular weight substance was increased after digestion by heparitinase (lane 3) and by chondroitinase ABC (lane 4). Lyases that digest different glycosaminoglycans had no effect (not shown). These results indicated that the components in the inhibitory CsCl sample are heparan/chondroitin sulfate proteoglycan and entactin.

Characterization of the Inhibitory Activity

The above fractionation studies suggested that the inhibitory activity may involve proteoglycan and entactin. To analyze further the properties of the inhibitory activity, we submitted the CsCl preparation to several treatments followed by bioassay. The results are shown in Table II. The inhibitor appears to be heat stable but trypsin sensitive suggesting that protein is important in expression of the inhibitory activity. The ability of heparitinase or chondroitinase ABC to eliminate the inhibitory activity suggests the involvement of both heparan and chondroitin sulfate glycosaminoglycans in the inhibitory activity. The products of lyase digestion (i.e., glycosaminoglycan fragments plus core protein) were not active. Also, purified heparin, heparan sulfate, chondroitin sulfate (up to 900 U) had no effect. Table II shows that the inhibitory activity itself is trypsin sensitive and not resistant to chondroitinase ABC or heparitinase. The inhibitory activity that does not react with heparitinase or chondroitinase ABC is chondroitin sulfate or heparan sulfate proteoglycan.

Table II. Effects of Selected Treatments on the Inhibitory Activity

| Treatment                  | Percent of remaining inhibitory activity* |
|----------------------------|------------------------------------------|
| None                       | 100 ± 2                                   |
| Heat: 95°C, 15 min         | 100 ± 2                                   |
| Trypsin                    | 0 ± 2                                     |
| Chondroitinase ABC         | 5 ± 5                                     |
| Heparitinase               | 10 ± 5                                    |

Inhibitory sample of CsCl preparation (POOL A, Fig. 4) was treated with heat or with either trypsin (100 µg/ml), chondroitinase ABC (0.2 U/ml), or heparitinase (1 U/ml) for 3 h at 37°C. Inhibitory titer (cf. Fig. 3) was determined after treatments. Data are averages of quadruplicate assays in three separate experiments, presented ± SD of the means.

* Starting activity = 160 NIU/ml.
The inhibitory pool from the CsCl centrifugation (POOL A, Fig. 4) was shown to be free of laminin but yet retained the capacity to interact with laminin and inactivate its neurite-promoting activity. To define further the nature of this association, we examined whether antibodies which bind to laminin but do not block its neurite-promoting activity. To test whether a particular sequence of substratum additions was critical for inhibitory activity, dilutions of the inhibitor were presented to wells before addition of the laminin, simultaneously with the laminin, or after preincubation with laminin in tubes. The results are shown in Fig. 8. The inhibitor retained its inhibitory effects regardless of the presentation sequence. However, the inhibitor exhibited the greatest potency (i.e., had the highest titer) when allowed to bind to the substratum before the addition of laminin and when preincubated with the laminin in solution before addition to the polycationic substratum.

**Antibodies Bound to Laminin Protect Its Neurite-promoting Activity from Inhibition**

The inhibitory pool from the CsCl centrifugation (POOL A, Fig. 4) was shown to be free of laminin but yet retained the capacity to interact with laminin and inactivate its neurite-promoting activity. To define further the nature of this association, we examined whether antibodies which bind to laminin but do not block its neurite-promoting activity. This approach used purified RN22 laminin and antibodies that bind to laminin but do not block its neurite-promoting activity. The results are shown in Table III. When RN22 laminin was preincubated with polyclonal antibodies raised against rat yolk sac tumor laminin, which do not block RN22 laminin activity, its neurite-promoting activity was minimally decreased by the inhibitor. Similarly, pretreatment of the RN22 laminin with 2E8 anti–human laminin monoclonal antibody also prevented inhibition. Since the 2E8 epitope on laminin is located at the cross-region of the laminin molecule (Engvall et al., 1986), this region of laminin might participate in the interaction between the inhibitor and laminin resulting in inhibition.

The partially purified inhibitor contains relatively high levels of the laminin-binding protein, entactin, which copurified with the inhibitory proteoglycan even under conditions which separated inhibitory activity from laminin neurite-promoting activity (i.e., isopycnic centrifugation). Like the 2E8 antibody, entactin is known to bind to laminin near the cross-region of laminin (Paulsson et al., 1987). Thus, we examined whether anti–entactin antibodies could interfere with the ability of the inhibitor to interact with laminin. The results are presented in Table III. Entactin antibodies, which do not by themselves interfere with the neurite-promoting activity of RN22 laminin (a preparation containing entactin), did prevent the inhibition from occurring.

In related experiments, anti–entactin antibodies were shown to be immunoreactive with the inhibitory material as well as with various tested laminin preparations. To further...
examine the role of entactin in the inhibitory activity, the isolated inhibitory fraction (CsCl Pool A, Fig. 4) was fractionated by isopycnic centrifugation run under dissociating conditions (in the presence of 2 M guanidine-HCl). A high buoyant density fraction containing heparan/chondroitin sulfate proteoglycan, but no entactin, was obtained that contained ~60% of the original inhibitory activity. However, the laminin preparation used in these assays contained entactin immunoreactivity. All preparations of laminin tested contained substantial entactin immunoreactivity and conditions required to dissociate entactin from laminin (see Paulsson et al., 1987) compromised the neurite-promoting activity of isolated laminin. Further study using carefully characterized preparations of laminin and entactin and neurite-promoting laminin fragments which do not associate with entactin will be required to assess whether entactin is required for the inhibitory activity.

Discussion

Here we report a first characterization of a material that can bind to laminin and interfere with its ability to promote neurITE outgrowth from cultured neurons. This material has been isolated from medium conditioned by RN22 Schwannoma cells by ion-exchange chromatography followed by isopycnic centrifugation. The inhibitory material contains proteoglycan based upon its high affinity for cationic resin, high buoyant density, large heterodisperse appearance on SDS gels, ability to become labeled with inorganic radiosulfate, sensitivity to trypsin and certain glycosaminoglycan lyases, and heat stability. The proteoglycan-containing material obtained from the CsCl density gradient also contained a substantial amount of the sulfated, 150-kD laminin-binding protein, entactin. The fact that the entactin sediments in the high density fraction, which is devoid of laminin, suggests that entactin retains an association with the inhibitory proteoglycan-containing material.

The proteoglycan associated with the inhibitory activity is apparently different from another laminin-binding proteoglycan in RN22 medium described by Davis et al. (1987) which has a lower density, higher molecular weight, and does not inhibit laminin neurite-promoting activity. In ion-exchange chromatography, much of the total RN22-conditioned medium laminin co-eluted with proteoglycans under high...
Table III. Antibody Interference of the Inhibitors Action on the Neurite-promoting Activity of RN22 Laminin

| Substratum (neurons bearing neurites) | Antibody treatment | Laminin | Plus inhibitor |
|-------------------------------------|--------------------|---------|---------------|
| None                                | %                  | %       |               |
| Controls (preimmune anti-NF, anti-FN) | 84                 | 0       |               |
| Anti-rat yolk sac laminin           | 75–85              | 0       |               |
| Anti-human laminin No. 2E8          | 75                 | 74      |               |
| Anti-entactin                        | 83                 | 70      |               |
| Anti-entactin                        | 85                 | 76      |               |

RN22 laminin (25 ng) was incubated in 6-mm-diam polyornithine-wells for 2 h. The laminin-polyornithine substratum was treated with PBS containing 1% BSA, followed by a 30-min incubation with PBS alone or PBS containing 1:50 dilutions of the following antibodies: polyclonal anti-human fibronectin (FN), monoclonal anti-neurofilament (NF), polyclonal anti-rat laminin, monoclonal anti-rat laminin No. 2E8, or polyclonal anti-mouse entactin. Without removing the antibodies, inhibitor (100 NIH/μl; CsCl inhibitory fraction) was added for 2 h and then the wells were washed. CG3 neurons (103/well) were seeded and the percentage of neurons bearing neurites was determined 4 h later by scoring 50–100 neurons per well. Conditions were replicated eight times in four separate experiments. Standard deviations were <10%.

salt from DEAE and was active in promoting neurites (cf. Fig. 1). When this laminin–proteoglycan pool was refractionated on a second DEAE column, only half of the loaded laminin antigen eluted with the proteoglycans and a substantial amount of laminin now eluted with less salt independent of proteoglycan (cf. Fig. 2). Only the proteoglycan-associated laminin lacked neurite-promoting activity. Subsequent analysis of this material (POOL II, Fig. 2) indicated the presence of an inhibitor of the associated laminin. The inhibitory activity could be destroyed by glycosaminoglycan lyase, which resulted in the reexpression of laminin neurite-promoting activity. Conversely, the laminin could be selectively denatured by heat, which apparently caused release of the inhibitor.

Chromatography and enzyme digestions indicate that the proteoglycan-associated inhibitor is degraded and inactivated by heparitinase or chondroitinase (Fig. 5 and Table II), suggesting the involvement of both heparan and chondroitin sulfate glycosaminoglycans in the inhibitory activity. The inhibitor is heat stable but trypsin sensitive, suggesting an intact protein to be important in the manifestation of the inhibitory activity. Additional evidence for the role of an intact proteoglycan in the inhibitory activity was obtained by growing RN22 cultures in the presence of 4-methylumbelliferyl-β-D-xyloside, a competitive inhibitor of glycosaminoglycan addition to proteoglycan core protein (Ratner et al., 1985; Galligani et al., 1975). Conditioned medium from xyloside treated RN22 cells contains only a small fraction of the inhibitory activity of that of untreated cells.

Proteoglycans found in culture conditioned media are thought to be derived from membrane-associated proteoglycan (Jalkanen et al., 1987) and a membrane fraction from RN22 cells contains a proteoglycan with properties very similar to inhibitor isolated from the conditioned medium (i.e., similar fractionation, appearance by autoradiography, and lyase inactivations). The regulation of proteoglycan synthesis and deposition may dictate whether laminin expresses its inherent neurite-promoting activity. The degradation of proteoglycan by specific lyases may remove the inhibition and restore neurite-promoting activity to a previously suppressed substratum. Thus, laminin neurite-promoting activity may depend as much on a fine tuning of proteoglycan synthesis and degradation as on laminin production and its cell surface or extracellular deposition.

Laminin preparations contain variable amounts of entactin, a sulfated protein that binds to a region near the cross region of laminin (Paulsson et al., 1987). Since entactin itself can bind laminin, but also copurifies with the inhibitor even through high ionic strength conditions, entactin may have the ability to interact with both laminin and the inhibitor. Anti-entactin antibodies prevent the inhibitor from blocking laminin neurite-promoting activity. Also, the monoclonal antibody 2E8 is known to bind to the cross region of rat laminin and, without diminishing neurite-promoting activity (Davis et al., 1987; Engvall et al., 1986), will protect the neurite-promoting activity of laminin. Thus, the ability of the inhibitor to interact with laminin may depend on its association with the cross region of the laminin tertiary structure, a region different from the postulated neurite-promoting domain at the end of the 400-kD long arm (Edgar et al., 1984; Engvall et al., 1986). Through interaction with the cross region of the laminin molecule, the inhibitor may influence the distant neurite-promoting site either directly, by additional binding to another portion of the laminin molecule, or indirectly, by inducing laminin conformational changes. The ability of the 2E8 and anti-entactin antibodies to protect the neurite-promoting activity of laminin raises the possibility that entactin or other components may mediate the formation of laminin complexes which modulate the potential neurite-promoting activity of laminin in basement membranes.

Schwannoma cells have been used in this study as a model for Schwann cells in vitro. Recently we have established purified populations of rat sciatic nerve Schwann cells and have found that their conditioned media also contain activity which inhibits neuritic outgrowth in response to laminin. The Schwann cell inhibitory activity had properties identical to the RN22 inhibitor (unpublished results). Future studies will need to address the inhibitors presence and function in vivo.

The authors wish to acknowledge the expert technical assistance of Ms. Eleanor Hewitt.

This work was supported by National Science Foundation grant BNS 86-17034 and National Institutes of Health grants NS 17034, NS 25011, and DK 30051.

Received for publication 21 December 1988 and in revised form 9 May 1989.

References

Akers, R. M., D. F. Mosher, and J. E. Lilien. 1981. Promotion of retinal neurite outgrowth by substratum-bound fibronectin. *Dev. Biol.* 86:179–188.

Akeson, R., and S. L. Warren. 1986. PC12 adhesion and neurite formation on selected substrates are inhibited by some glycosaminoglycans and a fibronectin-derived tetrapeptide. *Exp. Cell Res.* 162:347–362.

Alstadj, S. P., P. A. Hebd, A. E. Chung, and W. H. Eaglestein. 1987. Effect of basement membrane entactin on epidermal cell attachment and growth. *J. Invest. Derm.* 88:55–59.

Barbin, G., M. Manthorpe, and S. Varon. 1984. Purification of chick eye
Ciliary Neurorontrophic Factor (CNTF). J. Neurochem. 43:1468-1478.
Baron von Evercooren, A., H. K. Kleinman, S. Ohno, P. Marangos, P. Schwartz, and M. E. Dobois-Dale. 1982. Nerve growth factor, laminin and fibronectin promote neurite growth in human fetal sensory ganglia cultures. J. Neurosci. 8:179-194.
Bartoldi, P. M., and R. C. Page. 1985. A microdetermination method for assaying glycosaminoglycans and proteoglycans. Anal. Biochem. 150:320-324.
Bottenstein, J. E., and G. H. Sato. 1979. Growth of a rat neuroblastoma cell line in serum-free supplemented medium. Proc. Natl. Acad. Sci. USA. 76:514-517.
Brennan, M. J., A. Oldberg, E. G. Hayman, and E. Ruoslahti. 1983. Effect of a proteoglycan produced by rat tumor cells on their adhesion to fibronectin-collagen substrata. Cancer Res. 43:4302-4307.
Carbonetto, S., M. M. Grander, and D. C. Turner. 1983. Nerve fiber growth in culture on fibronectin, collagen and glycosaminoglycan substrates. J. Neurosci. 3:2324-2335.
Carlin, B., R. Jaffe, B. L. Bender, and A. E. Chang. 1981. Entactin: a novel basal lamina-associated sulfated glycoprotein. J. Biol. Chem. 256:5209-5214.
Corrigan, F. 1978. Induction of neurite outgrowth by a conditioned medium factor bound to culture substratum. Proc. Natl. Acad. Sci. USA. 75:5210-5213.
Davis, G. E., M. Manthorpe, E. Engvall, and S. Varon. 1985a. Isolation and characterization of rat Schwannoma neurite-promoting factor: Evidence that the factor contains laminin. J. Neurosci. 5:2662-2671.
Davis, G. E., S. Varon, E. Engvall, and M. Manthorpe. 1985b. Substratum-binding neurite promoting factors: relationships to laminin. Trends Neurosci. 8:528-532.
Davis, G. E., G. Kieser, E. Engvall, C. Cornbrooks, S. Varon, and M. Manthorpe. 1987. Association of laminin with heparan and chondroitin sulfate-bearing proteoglycans in neurite-promoting complexes from Schwannoma cells. Neurochem. Res. 12:909-921.
Dziadek, M., D. Edgar, M. Paulsson, R. Timpl, and R. Fleischmajar. 1986. Basement membrane proteins produced by Schwann cells and in neurofibromatosis. Ann. NY Acad. Sci. 486:248-259.
Edgar, D., R. Timpl, and H. Thoenen. 1984. The heparin-binding domain of laminin is responsible for its effects on neurite outgrowth and neuronal survival. EMBO (Eur. Mol. Biol. Organ.) J. 3:1463-1468.
Edgar, D., R. Timpl, and H. Thoenen. 1988. Structural requirements for the stimulation of neurite outgrowth by two variants of laminin and their inhibition by antibodies. J. Cell Biol. 106:1299-1306.
Engvall, E., 1980. Enzyme immunoassay: ELISA and EMIT. Methods Enzymol. 70:419-439.
Engvall, E., G. E. Davis, K. Dickerson, E. Ruoslahti, S. Varon, and M. Manthorpe. 1986. Mapping of domains in human laminin using monoclonal antibodies: localization of the neurite-promoting site. J. Cell Biol. 103:2457-2465.
Engvall, E., T. Kruisius, V. Wewer, and E. Ruoslahti. 1983. Laminin from rat yolk sac tumor: isolation, partial characterization and comparison with mouse laminin. Arch. Biochem. Biophys. 222:649-656.
Galligan, L., J. Hopwood, N. B. Schwartz, and A. Dorfman. 1975. Stimulation of synthesis of free chondroitin sulfate chains by B-D-xylosides in cultured cells. J. Biol. Chem. 250:5400-5406.
Hantez-Ambroise, D., M. Vigny, and J. Koenig. 1987. Heparan sulfate proteoglycan and laminin mediate two different types of neurite outgrowth. J. Neurosci. 7:2293-2304.
Jalkanen, M., A. Rapraeger, S. Saunders, and M. Bernfield. 1987. Cell surface proteoglycan of mouse mammary epithelial cells is shed by cleavage of its matrix-binding ectodomain from its membrane-associated domain. J. Cell Biol. 105:3087-3096.
Laemmli, U. K. 1970. Cleavage of structural protein during the assembly of the head of bacteriophage T4. Nature (Lond.) 227:680-685.
Lander, A. D., D. K. Fuji, D. Gospodarowicz, and L. F. Reichardt. 1982. Characterization of a factor that promotes neurite outgrowth. Evidence linking activity to a heparan sulfate proteoglycan. J. Cell Biol. 94:574-585.
Lander, A. D., D. K. Fuji, and L. F. Reichardt. 1983. Laminin is associated with the neurite outgrowth-promoting factors found in conditioned medium. Proc. Natl. Acad. Sci. USA. 82:2183-2187.
Lander, A. D., D. K. Fuji, and L. F. Reichardt. 1985. Purification of a factor that promotes neurite outgrowth: isolation of laminin and associated molecules. J. Cell Biol. 101:898-913.
Lowry, O. H., N. J. Rosenbrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-275.
Manthorpe, M., S. Varon, and R. Adler. 1981. Neurite-promoting factor in conditioned medium from RN22 Schwannoma cultures: bioassay, fractionation and properties. J. Neurochem. 37:759-767.
Manthorpe, M., E. Engvall, E. Ruoslahti, F. M. Longo, G. M. Davis, and S. Varon. 1983. Laminin promotes neuritic regeneration from cultured peripheral and central neurons. J. Cell Biol. 97:1882-1890.
Ott, V., E. Odermatt, J. Engel, H. Furtmayr, and R. Timple. 1982. Protease resistance and conformation of laminin. Eur. J. Biochem. 123:63-72.
Paulsson, M., M. Aumailely, R. Dutzmann, R. Timpl, K. Beck, and J. Engel. 1987. Laminin-nidogen complex: extraction with chelating agents and structural characterization. Eur. J. Biochem. 166:11-19.
Ratner, N., R. P. Bunge, and L. Glaser. 1985. A neuronal cell surface heparan sulfate proteoglycan is required for dorsal root ganglion neuron stimulation of Schwann cell proliferation. J. Cell Biol. 101:744-754.
Rogers, S. L., P. C. Letourneau, S. L. Palm, and L. T. Furcht. 1983. Neurite extension by peripheral and central nervous system neurons in response to substratum-bound fibronectin and laminin. Dev. Biol. 98:212-220.
Ruoslahti, E. 1988. Structure and Biology of proteoglycans. Annu. Rev. Cell Biol. 4:229-255.
Sakashita, S., E. Engvall, and E. Ruoslahti. 1980. Basement membrane glycoprotein laminin binds to heparin. FEBS (Fed. Eur. Biochem. Soc.) Lett. 116:243-246.
Towbin, H., T. Staehelin, and J. Gordon. 1979. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and applications. Proc. Natl. Acad. Sci. USA. 76:4350-4354.
Wewer, U., M. Albrechtsen, M. Manthorpe, S. Varon, E. Engvall, and E. Ruoslahti. 1983. Human laminin isolated in nearly intact, biologically active form from placenta by limited proteolysis. J. Biol. Chem. 250:12654-60.